Recombinant antigens are used increasingly over native allergen extracts in the diagnosis of allergies. They are capable of binding IgE antibodies in a comparable way to natural allergens and they demonstrate good reactivity in in-vitro diagnostic tests. Meridian’s panel of recombinant allergens is ideally suited to developing quantitative allergy ELISA tests which can determine an individual’s specific IgE-profile.